Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation

Documenti analoghi

• Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
  di: Chan, Yi‐Hsin, et al.
  Pubblicazione: (2018)
• Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
  di: Chan, Yi-Hsin, et al.
  Pubblicazione: (2017)
• Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
  di: Chang, Shang-Hung, et al.
  Pubblicazione: (2017)
• The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
  di: Lee, Kuang-Tso, et al.
  Pubblicazione: (2018)
• Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
  di: Chan, Yi-Hsin, et al.
  Pubblicazione: (2020)